A5082226238- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Diseases and Immunity
- Diet, Metabolism, and Disease
- Esophageal and GI Pathology
- Pancreatic and Hepatic Oncology Research
- RNA modifications and cancer
- Gastroesophageal reflux and treatments
- Hepatitis C virus research
- Pancreatitis Pathology and Treatment
- Hepatitis B Virus Studies
- Vascular anomalies and interventions
- Cardiovascular Disease and Adiposity
- Cancer-related molecular mechanisms research
- Cancer Immunotherapy and Biomarkers
- RNA Research and Splicing
- Gastrointestinal disorders and treatments
- Cardiovascular Health and Disease Prevention
- Gastrointestinal motility and disorders
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Lung Cancer Treatments and Mutations
- Abdominal vascular conditions and treatments
- Cardiovascular Function and Risk Factors
- Alcohol Consumption and Health Effects
Shimane University Hospital
2009-2025
Shimane University
2013-2024
Tokyo Metropolitan University
2023
Osaka Metropolitan University
2023
Gifu Municipal Hospital
2023
Saga University
2023
Hiroshima General Hospital
2023
Kawasaki Medical School
2023
Yokohama City University
2023
Ogaki Municipal Hospital
2023
The multimodal activities of farnesoid X receptor (FXR) agonists make this class an attractive option to treat nonalcoholic steatohepatitis. safety and efficacy tropifexor, FXR agonist, in a randomized, multicenter, double-blind, three-part adaptive design, phase 2 study, patients with steatohepatitis were therefore assessed. In Parts A + B, 198 randomized receive tropifexor (10-90 μg) or placebo for 12 weeks. Part C, 152 140 µg, 200 µg (1:1:1) 48 primary endpoints tolerability end-of-study,...
Nonalcoholic steatohepatitis (NASH) is an active form of nonalcoholic fatty liver disease. Risk factors for NASH include type 2 diabetes mellitus (T2DM) and obesity. Sodium-glucose cotransporter (SGLT2) inhibitors used to treat T2DM prevent glucose reabsorption in the kidney increase urinary excretion. Dapagliflozin a potent, selective SGLT2 inhibitor that reduces hyperglycemia patients with has been demonstrated reduce some complications associated rodent models.To assess efficacy safety...
Metabolic dysfunction-associated steatotic liver disease (MASLD) was recently proposed as an alternative concept to nonalcoholic fatty (NAFLD). We aimed investigate the prognosis of patients with biopsy-confirmed MASLD using data from a multicenter study.
Acid suppressive agents including proton pump inhibitors (PPIs) are used as first-line treatment for various acid-related gastrointestinal disorders. Although known to profoundly reduce gastric acid production, their influence on inhibition of secretion part the function tract microbiome remains be elucidated. The aim present study was examine effects PPI usage oral and gut microbiota in healthy volunteers.Ten adult volunteers receiving no medications were enrolled. We obtained fecal,...
Abstract Aim The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing worldwide. aim this study was to determine the recent and clinical characteristics NAFLD in Japan. Methods This initially included 410 061 retrospectively enrolled adults from medical health checkup registry for metabolic syndrome, chronic kidney disease, Japan (MIRACLE‐J; UMIN‐CTR no. UMIN000049419), who were evaluated between 2014 2018 at 13 centers Individuals consuming >20 g alcohol/day or with...
Abstract Purpose: The development of hepatocellular carcinoma is associated with the chronic inflammation liver caused by various factors such as hepatitis B or C virus infection. Previously, we reported DNA binding protein A (dbpA) a candidate molecule that can accelerate inflammation-induced hepatocarcinogenesis. DbpA belongs to Y-box family, and protein-1 (YB-1), prototype member this be prognostic marker malignant diseases other than carcinoma. purpose study examine significance...
Summary Aims A multi‐stakeholder consensus has proposed MASLD (metabolic dysfunction‐associated steatotic liver disease). We aimed to investigate the pathological findings related mid‐term mortality of patients with biopsy‐proven in Japan. Methods enrolled 1349 MASLD. The observational period was 8010 person years. evaluated independent factors associated by Cox regression analysis. also investigated profiles using data‐mining Results prevalence MASH and stage 3/4 fibrosis observed 65.6%...
ABSTRACT It remains unclear whether alcohol intake and cardiometabolic factors are simultaneously associated with liver fibrosis progression in Japanese obese patients. This study investigated influencing using the Aspartate Aminotransferase/Platelet Ratio Index (APRI), which does not include age. We conducted a cross‐sectional of 26 737 (BMI ≥ 25 kg/m 2 ) adults undergoing health checkups. Steatotic disease (SLD) was diagnosed via ultrasonography. Clinical characteristics were analysed...
The relationship between baseline serum albumin level and long-term prognosis of patients with nonalcoholic fatty liver disease (NAFLD) remains unknown. This is a sub-analysis the CLIONE (Clinical Outcome Nonalcoholic Fatty Liver Disease) study. main outcomes were: death or orthotopic transplantation (OLT), liver-related death, events (hepatocellular carcinoma [HCC], decompensated cirrhosis, gastroesophageal varices/bleeding). 1383 Japanese biopsy-confirmed NAFLD were analyzed. They divided...
Abstract Background and Aims Because the accuracy of Fibrosis‐4 (FIB‐4) index for predicting liver fibrosis changes with age, need different cut‐offs in various age groups has frequently been discussed. We developed age‐independent score, Fibrosis‐3 (FIB‐3) index, have shown its usefulness patients metabolic dysfunction‐associated steatotic disease (MASLD). This study aimed to validate diagnostic ability FIB‐3 predict progression using a large new patient cohort. Methods The was analyzed by...
There are no reports regarding the efficacy of sodium-glucose cotransporter 2 inhibitor (SGLT2i) and dipeptidyl peptidase 4 (DPP4i) administrations in nonalcoholic fatty liver disease (NAFLD) patients without type diabetes mellitus. The purpose this study was to evaluate those drugs such patients. NAFLD mellitus were enrolled single center double-blind randomized prospective study, allocated receive either dapagliflozin or teneligliptin for 12 weeks. Laboratory variables body compositions...
Non-alcoholic fatty liver disease (NAFLD) has a wide spectrum, eventually leading to cirrhosis and hepatic carcinogenesis. We previously reported that series of microRNAs (miRNAs) mapped in the 14q32.2 maternally imprinted gene region (Dlk1-Dio3 mat) are related NAFLD development progression mouse model. examined suitability miR-379, circulating Dlk1-Dio3 mat miRNA, as human biomarker.Eighty patients were recruited for this study. miR-379 was selected from putative miRNA cluster because it...
As it is not practical to perform regular screening for hepatocellular carcinoma (HCC) in all patients with non-alcoholic fatty liver disease (NAFLD), there a need identify NAFLD who are at high risk HCC. Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+ -M2BP) has been shown be surrogate marker predicting HCC as well fibrosis chronic hepatitis B and C. The aim of this study was investigate whether WFA+ -M2BP predicts development patients.Serum retrospectively measured 331...
The purpose of the present study was to investigate clinical significance highly sensitive fucosylated fraction α-fetoprotein (hs-AFP-L3) in patients with chronic liver disease (CLD) and low serum (AFP) concentration.A total 241 being treated at our institute CLD AFP concentration (3-10 ng/mL) were investigated retrospectively. We measured percentage AFP-L3 using a µTAS Wako i30 device. possible presence hepatocellular carcinoma (HCC) thoroughly by various examinations carried out from 1...
Impacts of platelet counts at the time liver biopsy on hepatocellular carcinoma (HCC) development in patients with nonalcoholic fatty disease (NAFLD) remain unknown. The aim this study was to investigate prognostic value biopsy-confirmed NAFLD using data from a multicenter study.One thousand three hundred ninety-eight were included subanalysis CLIONE (Clinical Outcome Nonalcoholic Fatty Liver Disease) Asia study. specimens pathologically diagnosed, and histologically scored NASH Clinical...
The efficacy of repeated lusutrombopag administration for thrombocytopenia in patients with chronic liver disease who undergo two or more planned invasive procedures is unknown. We herein report our findings regarding the effects given to avoid platelet transfusion a patient and thrombocytopenia. count showed positive response treatment prior initial procedure treat hepatoma, so was not necessary. In conclusion, may be useful drug those undergoing procedures.
Background and study aims Recurrence of common bile duct stones (CBDS) in patients treated with endoscopic sphincterotomy (ES) can lead to deterioration their quality life. Although the pathology related factors are unclear, we speculated that proton pump inhibiter (PPI) administration increases risk CBDS recurrence by altering bacterial mixture duct. Patients methods The primary endpoint this retrospective was recurrence-free period. Several independent variables considered have a...